Glenmark's generic Aggrenox gets FDA nod
Glenmark Pharmaceuticals has received the Food and Drug Administration’s blessing for its aspirin and extended-release dipyridamole capsules, in a 25 mg/200 mg dosage strength.
The product is a generic of Boehringer Ingelheim’s Aggrenox capsules, 25 mg/200 mg.
Aggrenox capsules, 25 mg/200 mg had a market value of approximately $165.6 million for the 12 months ended March 2019, according to IQVIA data.
The product is a generic of Boehringer Ingelheim’s Aggrenox capsules, 25 mg/200 mg.
Aggrenox capsules, 25 mg/200 mg had a market value of approximately $165.6 million for the 12 months ended March 2019, according to IQVIA data.